P3-255: ASSAY OF PLASMA PHOSPHORYLATED TAU PROTEIN (THREONINE 181) AND TOTAL TAU PROTEIN IN VASCULAR DEMENTIA, PARKINSON'S DISEASE, FRONTOTEMPORAL DEMENTIA, AND EARLY-STAGE ALZHEIMER'S DISEASE

2006 ◽  
Vol 14 (7S_Part_22) ◽  
pp. P1172-P1172
Author(s):  
Shieh-Yueh Yang ◽  
Ming-Jang Chiu ◽  
Ta-Fu Chen ◽  
Chin-Hsien Lin ◽  
Wen-Ping Chen ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Parkinson’S Disease ◽  
Alzheimer's Disease ◽  
Vascular Dementia ◽  
Frontotemporal Dementia ◽  
Tau Protein ◽  
Early Stage ◽  
Phosphorylated Tau ◽  
Total Tau ◽  
Phosphorylated Tau Protein

Assay of Plasma Phosphorylated Tau Protein (Threonine 181) and Total Tau Protein in Early-Stage Alzheimer’s Disease

2018 ◽  
Vol 61 (4) ◽  
pp. 1323-1332 ◽  
Author(s):  
Che-Chuan Yang ◽  
Ming-Jang Chiu ◽  
Ta-Fu Chen ◽  
Hui-Ling Chang ◽  
Bing-Hsien Liu ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Tau Protein ◽  
Early Stage ◽  
Phosphorylated Tau ◽  
Total Tau ◽  
Phosphorylated Tau Protein

Examination of phosphorylated tau protein as a PHF-precursor at early stage alzheimer's disease

1995 ◽  
Vol 16 (3) ◽  
pp. 433-445 ◽  
Author(s):  
Robert Y.K. Lai ◽  
Herman N.-J. Gertz ◽  
Damon J. Wischik ◽  
John H. Xuereb ◽  
Elizabeth B. Mukaetova-Ladinska ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Tau Protein ◽  
Early Stage ◽  
Phosphorylated Tau ◽  
Phosphorylated Tau Protein

scholarly journals Cerebrospinal Fluid Biomarkers for Kii Amyotrophic Lateral Sclerosis/Parkinsonism-Dementia Complex

2013 ◽  
Vol 2013 ◽  
pp. 1-4
Author(s):  
Yui Nakayama ◽  
Satoru Morimoto ◽  
Misao Yoneda ◽  
Shigeki Kuzuhara ◽  
Yasumasa Kokubo
Keyword(s):  
Alzheimer’S Disease ◽  
Parkinson’S Disease ◽  
Alzheimer's Disease ◽  
Parkinson's Disease ◽  
Amyotrophic Lateral Sclerosis ◽  
Cerebrospinal Fluid ◽  
Enzyme Linked Immunosorbent Assay ◽  
Phosphorylated Tau ◽  
Total Tau ◽  
Lateral Sclerosis

Objective. Amyotrophic lateral sclerosis/parkinsonism-dementia complex is classified as one of the tauopathies. Methods. The total tau, phosphorylated tau, and amyloid β42 levels were assayed in cerebrospinal fluid from patients with Kii amyotrophic lateral sclerosis/parkinsonism-dementia complex (), Alzheimer’s disease (), Parkinson’s disease (), amyotrophic lateral sclerosis (), and controls () using specific enzyme-linked immunosorbent assay methods. Results. Total tau and phosphorylated tau did not increase and amyloid β42 was relatively reduced in Kii amyotrophic lateral sclerosis/parkinsonism-dementia complex. Relatively reduced amyloid β42 might discriminate Kii amyotrophic lateral sclerosis/parkinsonism-dementia complex from amyotrophic lateral sclerosis and Parkinson’s disease, and the ratios of phosphorylated-tau to amyloid β42 could discriminate Kii amyotrophic lateral sclerosis/parkinsonism-dementia complex from Alzheimer’s disease. Conclusions. Cerebrospinal fluid analysis may be useful to differentiate amyotrophic lateral sclerosis/parkinsonism-dementia complex from Alzheimer’s disease, amyotrophic lateral sclerosis, and Parkinson’s disease.

Sign in / Sign up

Export Citation Format

Share Document